Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/37677 http://dx.doi.org/10.1371/journal.pone.0096067 |
Resumo: | The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced glycation end-products (sRAGE) and influenced by immunosuppressive or lipid-lowering therapy. Twenty-three GPA patients and 20 controls were evaluated for HMGB1- and sRAGE levels and for carotid atherosclerosis using ultrasound to determine intima-media thickness (IMT). in vitro the effect of atorvastatin on the production of HMGB1 by lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVEC) was assessed. Serum HMGB1 and sRAGE levels did not differ between patients and controls. A negative correlation was found between sRAGE and maximum IMT but HMGB1 and carotid IMT were not related. HMGB1 levels were reduced in GPA patients on statins and prednisolone. in vitro, atorvastatin reduced HMGB1 levels in supernatants of activated HUVEC. in conclusion, carotid IMT is inversely correlated with sRAGE levels but not with HMGB1 levels. Statins and prednisolone are associated with reduced serum HMGB1 levels and atorvastatin decreases HMGB1 release by activated HUVEC in vitro, indicating an additional anti-inflammatory effect of statins. |
id |
UFSP_f82b9b70d32a7682330fd654ed58ebfa |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/37677 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Souza, Alexandre Wagner Silva de [UNIFESP]Leeuw, Karina devan Timmeren, Mirjan M.Limburg, Pieter C.Stegeman, Coen A.Bijl, MarcWestra, JohannaKallenberg, Cees G. M.Univ GroningenMartini HospUniversidade Federal de São Paulo (UNIFESP)2016-01-24T14:37:08Z2016-01-24T14:37:08Z2014-04-28Plos One. San Francisco: Public Library Science, v. 9, n. 4, 6 p., 2014.1932-6203http://repositorio.unifesp.br/handle/11600/37677http://dx.doi.org/10.1371/journal.pone.0096067WOS000346241800026.pdf10.1371/journal.pone.0096067WOS:000346241800026The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced glycation end-products (sRAGE) and influenced by immunosuppressive or lipid-lowering therapy. Twenty-three GPA patients and 20 controls were evaluated for HMGB1- and sRAGE levels and for carotid atherosclerosis using ultrasound to determine intima-media thickness (IMT). in vitro the effect of atorvastatin on the production of HMGB1 by lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVEC) was assessed. Serum HMGB1 and sRAGE levels did not differ between patients and controls. A negative correlation was found between sRAGE and maximum IMT but HMGB1 and carotid IMT were not related. HMGB1 levels were reduced in GPA patients on statins and prednisolone. in vitro, atorvastatin reduced HMGB1 levels in supernatants of activated HUVEC. in conclusion, carotid IMT is inversely correlated with sRAGE levels but not with HMGB1 levels. Statins and prednisolone are associated with reduced serum HMGB1 levels and atorvastatin decreases HMGB1 release by activated HUVEC in vitro, indicating an additional anti-inflammatory effect of statins.GUIDE InstituteJan Kornelis de Cock InstituteUniv Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, NetherlandsUniv Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, NetherlandsUniv Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, NetherlandsUniv Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, NetherlandsMartini Hosp, Groningen, NetherlandsUniversidade Federal de São Paulo, Escola Paulista Med Unifesp EPM, Div Rheumatol, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med Unifesp EPM, Div Rheumatol, São Paulo, BrazilWeb of Science6engPublic Library SciencePlos OneImpact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000346241800026.pdfapplication/pdf369050${dspace.ui.url}/bitstream/11600/37677/1/WOS000346241800026.pdf4c965f844670bfa7fedbff7c0e9e2489MD51open accessTEXTWOS000346241800026.pdf.txtWOS000346241800026.pdf.txtExtracted texttext/plain24946${dspace.ui.url}/bitstream/11600/37677/2/WOS000346241800026.pdf.txt14328993f1a3b0fdc620997a92a12f40MD52open access11600/376772021-10-05 21:57:24.17open accessoai:repositorio.unifesp.br:11600/37677Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:20:42.392146Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
title |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
spellingShingle |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis Souza, Alexandre Wagner Silva de [UNIFESP] |
title_short |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
title_full |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
title_fullStr |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
title_full_unstemmed |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
title_sort |
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis |
author |
Souza, Alexandre Wagner Silva de [UNIFESP] |
author_facet |
Souza, Alexandre Wagner Silva de [UNIFESP] Leeuw, Karina de van Timmeren, Mirjan M. Limburg, Pieter C. Stegeman, Coen A. Bijl, Marc Westra, Johanna Kallenberg, Cees G. M. |
author_role |
author |
author2 |
Leeuw, Karina de van Timmeren, Mirjan M. Limburg, Pieter C. Stegeman, Coen A. Bijl, Marc Westra, Johanna Kallenberg, Cees G. M. |
author2_role |
author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Univ Groningen Martini Hosp Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Souza, Alexandre Wagner Silva de [UNIFESP] Leeuw, Karina de van Timmeren, Mirjan M. Limburg, Pieter C. Stegeman, Coen A. Bijl, Marc Westra, Johanna Kallenberg, Cees G. M. |
description |
The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced glycation end-products (sRAGE) and influenced by immunosuppressive or lipid-lowering therapy. Twenty-three GPA patients and 20 controls were evaluated for HMGB1- and sRAGE levels and for carotid atherosclerosis using ultrasound to determine intima-media thickness (IMT). in vitro the effect of atorvastatin on the production of HMGB1 by lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVEC) was assessed. Serum HMGB1 and sRAGE levels did not differ between patients and controls. A negative correlation was found between sRAGE and maximum IMT but HMGB1 and carotid IMT were not related. HMGB1 levels were reduced in GPA patients on statins and prednisolone. in vitro, atorvastatin reduced HMGB1 levels in supernatants of activated HUVEC. in conclusion, carotid IMT is inversely correlated with sRAGE levels but not with HMGB1 levels. Statins and prednisolone are associated with reduced serum HMGB1 levels and atorvastatin decreases HMGB1 release by activated HUVEC in vitro, indicating an additional anti-inflammatory effect of statins. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-04-28 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:37:08Z |
dc.date.available.fl_str_mv |
2016-01-24T14:37:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Plos One. San Francisco: Public Library Science, v. 9, n. 4, 6 p., 2014. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/37677 http://dx.doi.org/10.1371/journal.pone.0096067 |
dc.identifier.issn.none.fl_str_mv |
1932-6203 |
dc.identifier.file.none.fl_str_mv |
WOS000346241800026.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1371/journal.pone.0096067 |
dc.identifier.wos.none.fl_str_mv |
WOS:000346241800026 |
identifier_str_mv |
Plos One. San Francisco: Public Library Science, v. 9, n. 4, 6 p., 2014. 1932-6203 WOS000346241800026.pdf 10.1371/journal.pone.0096067 WOS:000346241800026 |
url |
http://repositorio.unifesp.br/handle/11600/37677 http://dx.doi.org/10.1371/journal.pone.0096067 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Plos One |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
6 |
dc.publisher.none.fl_str_mv |
Public Library Science |
publisher.none.fl_str_mv |
Public Library Science |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/37677/1/WOS000346241800026.pdf ${dspace.ui.url}/bitstream/11600/37677/2/WOS000346241800026.pdf.txt |
bitstream.checksum.fl_str_mv |
4c965f844670bfa7fedbff7c0e9e2489 14328993f1a3b0fdc620997a92a12f40 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460278961176576 |